RSS

immuno-oncology

Clinical stage biopharmaceutical company, X4 Pharmaceuticals, has secured $27 million in series B funding that will be used to advance its two lead drug candidates in clinical efficacy studies in immune-oncology and a pivotal study in a rare disease. more

News

UK based fund manager, Sixth Element Capital, has announced a £3 million investment in a spin out company from PhoreMost — NeoPhore. more

News

Aquila BioMedical

Aquila BioMedical and Macrophage Pharma partner on immuno-oncology programme

Preclinical contract research organisation (CRO), Aquila BioMedical — now part of Concept Life Sciences group, has secured an extended agreement with UK-based biotech firm, Macrophage Pharma, to support its preclinical immune-oncology programmes. more

News

The US Food and Drug Administration (FDA) has granted an award to clinical research infrastructure provider, Elligo Health Research to evaluate a harmonised data model that will help in the safety assessment of new oncology therapies. more

News

The latest report from business information and analytics provider, GlobalData, has indicated that immune-oncology (IO) will become the fifth pillar of cancer treatment, joining surgery, radiotherapy, chemotherapy and other targeted treatments. more

Analysis

Macrophage Pharma, an immune-oncology research and development (R&D) company that focuses on macrophage modulation in the tumour microenvironment (TME), has raised additional funding from Merck Ventures. more

News

Nanobiotix is expanding and accelerating its clinical development activities, including its head and neck cancer programme and immune-oncology programme. more

News

Kymab and Heptares Therapeutics have entered a strategic collaboration to discover, develop and commercialise novel antibody therapeutics targeting a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology. more

News

Pierre Fabre Médicament (PFM) has announced a strategic partnership with Inserm Transfert and Inserm’s academic partners to identify new therapeutic targets in immuno-oncology more

News

Catalent has signed an exclusive licencing agreement to access Excelimmune's antibody combination therapy technology platform, which has the potential to pave the way for more consistent, cost-effective production of antibody combinations. more

News

Advanced melanoma patients have been given new hope as an international trial has shown that a combination of the drugs iplimumab and nivolumab could shrink tumours in around 60% of cases. more

News